Our proprietary FAVORITE™   breath controlled nebulised  technology, developed to improve  effectiveness of inhaled drugs  and deliver better clinical outcomes  and shorter treatment times Vectura Group plc   Annual Report and Accounts 2017 Vectura Group plc Annual Report and Accounts 2017 TRANSFORMING THE LIVES OF AIRWA YS DISEASE PA TIENTS FAVORITE ™  inhalation 1  Latest WHO estimates, released in December 2016,    [Last accessed March 2018]. 2  National Heart, Lung and Blood Institute. What is asthma? Available from    [Last accessed March 2018]. 3  Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy. 2014; 7; 53–65. 4   [Last accessed March 2018]. 5  Latest WHO estimates, released in December 2016,    [Last accessed March 2018]..